Prospective Validation of the Prognostic Usefulness of Brain Natriuretic Peptide in Asymptomatic Patients With Chronic Severe Mitral Regurgitation
Rodolfo Pizarro, MD,
Oscar O. Bazzino, MD,
Pablo F. Oberti, MD,
Mariano Falconi, MD,
Federico Achilli, MD,
Anibal Arias, MD,
Juan G. Krauss, MD and
Arturo M. Cagide, MD*
Cardiology Division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Combined End Point According to BNP Values
Symptoms of congestive heart failure, left ventricular systolic dysfunction, or death (LVDSD) according to brain natriuretic peptide (BNP) values.
|
|
View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Receiver-Operator Curve Analysis
Incremental value of BNP  105 pg/ml when added to echocardiographic variables for the prediction of LVDSD (A: derivation and B: validation set). AV = atrial volume; EROA = effective regurgitant orifice area; ESD/BSA = end-systolic diameter corrected by body surface area; other abbreviations as in Figures 1 and 2.
|
|
|
